Impact of Strut Width in Periprocedural Myocardial Infarction: A Propensity-Matched Comparison Between Bioresorbable Scaffolds and the First-Generation Sirolimus-Eluting Stent

JACC: Cardiovascular Interventions

Volumn 8, Issue 7, 2015, Pages 900-909

  Kawamoto, Hiroyoshi ^a,b   Panoulas, Vasileios F ^a,b,c   Sato, Katsumasa ^a,b   Miyazaki, Tadashi ^a,b   Naganuma, Toru ^d   Sticchi, Alessandro ^a   Figini, Filippo ^a,b   Latib, Azeem ^a,b   Chieffo, Alaide ^a   Carlino, Mauro ^a   Montorfano, Matteo ^a   Colombo, Antonio ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b EMO GVM CENTRO CUORE COLUMBUS   (Italy)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d NEW TOKYO HOSPITAL   (Japan)

Author keywords

bioresorbable scaffold; first generation; periprocedural myocardial infarction; sirolimus eluting stent; strut width

Indexed keywords

RAPAMYCIN; CARDIOVASCULAR AGENT; EVEROLIMUS;

ADULT; ARTICLE; BIORESORBABLE SCAFFOLD; CARDIOVASCULAR MORTALITY; FEMALE; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PERIPROCEDURAL MYOCARDIAL INFARCTION; PRIORITY JOURNAL; REVASCULARIZATION; SIROLIMUS ELUTING CORONARY STENT; TREATMENT OUTCOME; ADVERSE EFFECTS; AGED; BIODEGRADABLE IMPLANT; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DEVICES; DRUG ELUTING STENT; INCIDENCE; ITALY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; PROSTHESIS; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL;

ABSORBABLE IMPLANTS; AGED; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; INCIDENCE; ITALY; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84931412314     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2015.02.011     Document Type: Article

References (37)

1. G.W. Stone, S.G. Ellis, and L. Cannon Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial JAMA 294 2005 1215 1223
2. M. Joner, A.V. Finn, and A. Farb Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202
3. M. Hamilos, J. Sarma, and M. Ostojic Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses Circ Cardiovasc Interv 1 2008 193 200
4. T. Kimura, T. Morimoto, and Y. Nakagawa Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry Circulation 125 2012 584 591
5. T. Kimura, T. Morimoto, and K. Kozuma Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART) Circulation 122 2010 52 61
6. T. Tada, R.A. Byrne, and I. Simunovic Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients J Am Coll Cardiol Intv 6 2013 1267 1274
7. S. Silber, S. Windecker, P. Vranckx, P.W. Serruys RESOLUTE All Comers Investigators Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial Lancet 377 2011 1241 1247
8. M.C. Morice, P.W. Serruys, J.E. Sousa for the RAVEL Study Group A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
9. S. Windecker, P.W. Serruys, and S. Wandel Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
10. K. Tandjung, M.W. Basalus, and H. Sen DUrable polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute integrity (DUTCH PEERS): rationale and study design of a randomized multicenter trial in a Dutch all-comers population Am Heart J 163 2012 557 562
11. P.W. Serruys, H.M. Garcia-Garcia, and Y. Onuma From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 33 2012 16 25b
12. Y. Onuma, and P.W. Serruys Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation 123 2011 779 797
13. Y. Onuma, D. Dudek, and L. Thuesen Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial J Am Coll Cardiol Intv 6 2013 999 1009
14. J.A. Ormiston, B. Webber, B. Ubod, M.W. Webster, and J. White Absorb everolimus-eluting bioresorbable scaffolds in coronary bifurcations: a bench study of deployment, side branch dilatation and post-dilatation strategies EuroIntervention 10 2015 1169 1177
15. J. Doostzadeh, L.N. Clark, S. Bezenek, W. Pierson, P.R. Sood, and K. Sudhir Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent Coron Artery Dis 21 2010 46 56
16. C. Briguori, C. Sarais, and P. Pagnotta In-stent restenosis in small coronary arteries: impact of strut thickness J Am Coll Cardiol 40 2002 403 409
17. J.J. Popma, L. Mauri, and C. O'Shaughnessy Frequency and clinical consequences associated with sidebranch occlusion during stent implantation using zotarolimus-eluting and paclitaxel-eluting coronary stents Circ Cardiovasc Interv 2 2009 133 139
18. A.J. Lansky, M. Yaqub, and J.B. Hermiller Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial EuroIntervention 6 Suppl J 2010 J44 J52
19. A. Prasad, M. Singh, A. Lerman, R.J. Lennon, D.R. Holmes Jr., and C.S. Rihal Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality J Am Coll Cardiol 48 2006 1765 1770
20. R.M. Califf, A.E. Abdelmeguid, and R.E. Kuntz Myonecrosis after revascularization procedures J Am Coll Cardiol 31 1998 241 251
21. L.O. Jensen, M. Maeng, and A. Kaltoft Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions J Am Coll Cardiol 50 2007 463 470
22. T. Muramatsu, Y. Onuma, H.M. Garcia-Garcia for the ABSORB-EXTEND Investigators Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials J Am Coll Cardiol Intv 6 2013 247 257
23. P. Vranckx, D.E. Cutlip, and R. Mehran Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies EuroIntervention 5 2010 871 874
24. W.K. Laskey, C.W. Yancy, and W.H. Maisel Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006 Circulation 115 2007 2352 2357
25. A.J. Lansky, and G.W. Stone Periprocedural myocardial infarction: prevalence, prognosis, and prevention Circ Cardiovasc Interv 3 2010 602 610
26. A. Prasad, and J. Herrmann Myocardial infarction due to percutaneous coronary intervention N Engl J Med 364 2011 453 464
27. J.F. Saucedo, R. Mehran, and G. Dangas Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting J Am Coll Cardiol 35 2000 1134 1141
28. S. Brugaletta, J. Gomez-Lara, and R. Diletti Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: insights from the ABSORB and SPIRIT trials Catheter Cardiovasc Interv 79 2012 219 228
29. D.W. Park, Y.H. Kim, and S.C. Yun Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention Eur Heart J 34 2013 1662 1669
30. A. Abizaid, J.R. Costa Jr., and A.L. Bartorelli The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled EuroIntervention 10 2015 1396 1401
31. P.W. Serruys, B. Chevalier, and D. Dudek A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial Lancet 385 2015 43 54
32. K. Thygesen, J.S. Alpert, H.D. White Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction Universal definition of myocardial infarction J Am Coll Cardiol 50 2007 2173 2195
33. V.R. Mandadi, M.C. DeVoe, and J.A. Ambrose Predictors of troponin elevation after percutaneous coronary intervention Am J Cardiol 93 2004 747 750
34. J.C. Blankenship, T. Haldis, and F. Feit Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy) Am J Cardiol 97 2006 1591 1596
35. Q. Cai, K.A. Skelding, A.T. Armstrong Jr., D. Desai, G.C. Wood, and J.C. Blankenship Predictors of periprocedural creatine kinase-myocardial band elevation complicating elective percutaneous coronary intervention Am J Cardiol 99 2007 616 620
36. W.J. van Gaal, F.A. Ponnuthurai, and J. Selvanayagam The Syntax score predicts peri-procedural myocardial necrosis during percutaneous coronary intervention Int J Cardiol 135 2009 60 65
37. E.J. Topol, D.B. Mark, A.M. Lincoff for the EPISTENT Investigators Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial Lancet 354 1999 2019 2024